Kyntra Bio, Inc. Receives Nasdaq Delisting Notice: Key Details for Investors
Key Points:
- Kyntra Bio, Inc. (NASDAQ: KYNB) has received a notice from the Nasdaq Stock Market regarding non-compliance with continued listing requirements.
- The company failed to meet the Nasdaq Global Select Market rule requiring at least \$50 million in total assets and total revenue for the most recent fiscal year (or two of the last three fiscal years), as stated under Listing Rule 5450(b)(3)(A).
- The deficiency is a result of revenue from FibroGen International being presented as “held for sale” (in discontinued operations) in 2024 and 2025, impacting total revenue calculations.
- Kyntra Bio currently does not meet alternative Nasdaq listing standards, including shareholders’ equity or market value of listed securities.
What Shareholders Need to Know:
- No Immediate Delisting: The notification has no immediate effect on the listing of Kyntra Bio’s common stock. Shares will continue to trade on Nasdaq for now.
- Compliance Plan Required: Kyntra Bio has until May 18, 2026, to submit a plan to Nasdaq outlining how it intends to regain compliance. If Nasdaq accepts the plan, the company may be granted an extension of up to 180 days (until September 29, 2026) to meet the listing standards.
- Potential Transfer to Nasdaq Capital Market: If unable to regain compliance with the Global Select Market rules, Kyntra Bio may consider transferring its listing to the Nasdaq Capital Market, which has less stringent requirements.
- Nasdaq’s Review Process: Nasdaq will evaluate Kyntra Bio’s compliance plan considering factors such as the likelihood of successful compliance, past compliance history, reasons for the current deficiency, upcoming corporate events, financial condition, and public disclosures.
- Price Sensitivity: The risk of eventual delisting or transfer to a less prestigious market tier may impact investor sentiment and share value. Shareholders should monitor developments closely as failure to regain compliance could lead to removal from the Nasdaq, affecting liquidity and visibility.
Additional Corporate Details:
- Company Name: Kyntra Bio, Inc. (formerly known as FibroGen Inc.)
- Address: 350 Bay Street, Suite 100 #6009, San Francisco, CA 94133
- Trading Symbol: KYNB
- Class of Security: Common Stock, \$0.01 par value
- Exchange: The Nasdaq Global Select Market
- Commission File Number: 001-36740
- Incorporation: Delaware
- EIN: 77-0357827
- General Counsel: John Alden (signed the 8-K report)
Investor Implications:
- This development is significant and potentially price-sensitive. While there is no immediate threat to the listing, investors should be aware of the timelines and possible outcomes, including delisting or transfer to a less stringent exchange.
- Any negative market reaction could lead to increased volatility in KYNB shares as the company works to resolve the listing deficiency.
- Shareholders should expect ongoing updates from the company as it responds to Nasdaq and takes steps to regain compliance or pursue alternative listing options.
Disclaimer:
This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with professional advisors before making any investment decisions. All information is based on official filings and may be subject to change as Kyntra Bio, Inc. responds to Nasdaq and regulatory requirements.
View KYNTRA BIO, INC. Historical chart here
